Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Association between plasma lipid levels and migraine in subjects agedor =50 years: preliminary data from the Zabùt Aging Project.

2008

We evaluated the association between lipid levels and migraine using cross-sectional, population-based data of 1809 subjects aged >= 50 years; 151 subjects with migraine and 1658 nonmigraineurs were included. Diagnosis of migraine was carried out using the criteria of the International Headache Society. The following plasma lipids were collected: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG). Only TC (p= 220 mg/dl) was significantly associated with migraine (OR [95% CI]=1.6 [1.1-2.3]); this association increased in elderly males with migraine (OR [95% CI]=3.8 [1.4-9.9]). According to our results, TC p…

Malemedicine.medical_specialtyMigraine DisordersPopulationDermatologychemistry.chemical_compoundTotal cholesterolInternal medicineEpidemiologyPlasma lipidsmedicineOdds RatioHumanseducationGeriatric AssessmentTriglyceridesLipoprotein cholesterolAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryCholesterolCholesterol HDLMigraine Epidemiology Cholesterol ElderlyAge FactorsGeneral MedicinePlasma levelsCholesterol LDLMiddle Agedmedicine.diseaseLipidsPsychiatry and Mental healthEndocrinologyMigrainechemistryItalylipids (amino acids peptides and proteins)Settore MED/26 - NeurologiaFemaleNeurology (clinical)businessNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis

2009

Abstract Background Recent findings have suggested that subjects with non-coronary atherosclerosis may show elevated prevalence of atherogenic dyslipidemia, including higher triglyceride levels, reduced HDL-cholesterol concentrations and increased levels of small, dense low-density lipoproteins (LDL). These three lipid abnormalities constitute the so-called “atherogenic-lipoprotein-phenotype” (ALP) but its predictive role in these patients still remains to be established. Methods We performed a 2-year follow-up study to assess clinical and biochemical predictors of cardiovascular events in 44 male patients (64 ± 5 years, BMI: 27 ± 3), 26 with peripheral arterial disease and 18 with abdomina…

Malemedicine.medical_specialtyMultivariate analysis1303 BiochemistryClinical Biochemistry10265 Clinic for Endocrinology and Diabetology610 Medicine & health1308 Clinical Biochemistry2704 Biochemistry (medical)Biochemistrychemistry.chemical_compoundRisk Factorsatherogenic dyslipidemiaInternal medicineDiabetes mellitusmedicineHumansFamily historyCoronary atherosclerosisDyslipidemiasPeripheral Vascular DiseasesUnivariate analysisTriglyceridebusiness.industryBiochemistry (medical)Cholesterol LDLGeneral MedicineMiddle AgedAtherosclerosismedicine.diseaseAbdominal aortic aneurysmPeripheralPhenotypechemistryCase-Control StudiesMultivariate AnalysisCardiologyAtherosclerosis HDL-cholesterol Triglycerides Small dense LDL Atherogenic lipoprotein phenotypebusinessAortic Aneurysm AbdominalFollow-Up Studies
researchProduct

Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey

2018

Aims: Familial hypercholesterolaemia (FH) accelerates atherosclerotic cardiovascular disease (ASCVD) and accordingly is the most potent hereditary cause of premature coronary heart disease. The association between telomere length (TL), a biological index of ageing, and FH has not been hitherto investigated. We addressed this question using data from the US National Health and Education National Surveys (NHANES, 1999-2002).Methods and results: We included individuals, who had TL measurements (with quantitative polymerase chain reaction method) and a phenotypic diagnosis of FH based on the Dutch Lipid Clinic Network (DLCN) criteria. Sample weights were applied for unequal probabilities of sel…

Malemedicine.medical_specialtyNational Health and Nutrition Examination SurveyCross-sectional studyPopulationFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumans030212 general & internal medicineeducationNational Health and Education National Surveyseducation.field_of_studyTelomere lengthbusiness.industryMiddle AgedTelomeremedicine.diseaseNutrition SurveysObesityConfidence intervalUnited StatesCross-Sectional StudiesQuartileFemaleCardiology and Cardiovascular MedicinebusinessFamilial hypercholesterolaemiaBody mass indexEuropean Heart Journal
researchProduct

Resveratrol Reverses Endothelial Nitric-Oxide Synthase Uncoupling in Apolipoprotein E Knockout Mice

2010

A crucial cause of the decreased bioactivity of nitric oxide (NO) in cardiovascular diseases is the uncoupling of the endothelial NO synthase (eNOS) caused by the oxidative stress-mediated deficiency of the NOS cofactor tetrahydrobiopterin (BH(4)). The reversal of eNOS uncoupling might represent a novel therapeutic approach. The treatment of apolipoprotein E knockout (ApoE-KO) mice with resveratrol resulted in the up-regulation of superoxide dismutase (SOD) isoforms (SOD1-SOD3), glutathione peroxidase 1 (GPx1), and catalase and the down-regulation of NADPH oxidases NOX2 and NOX4 in the hearts of ApoE-KO mice. This was associated with reductions in superoxide, 3-nitrotyrosine, and malondiald…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIISOD3SOD2ResveratrolAntioxidantsSuperoxide dismutaseMicechemistry.chemical_compoundApolipoproteins ESuperoxidesEnosMalondialdehydeInternal medicineStilbenesmedicineAnimalsGTP CyclohydrolaseMice KnockoutPharmacologychemistry.chemical_classificationReactive oxygen speciesbiologyReverse Transcriptase Polymerase Chain ReactionSuperoxide DismutaseChemistrySuperoxideMyocardiumTetrahydrobiopterinbiology.organism_classificationBiopterinIsoenzymesOxidative StressEndocrinologyBiochemistryResveratrolbiology.proteinRNATyrosineMolecular Medicinemedicine.drugJournal of Pharmacology and Experimental Therapeutics
researchProduct

Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

2011

Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers of Alzheimer's disease (AD). We examined the agreement between these biomarkers in a single center study of patients with AD of severity extending over a wide range. Forty seven patients (MMSE 21.4 ± 3.6, range 13-28 points) with incipient and probable AD underwent positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) and lumbar puncture for CSF assays of Aβ1-42, p-tau181, and t-tau. All findings were classified as either positive or negative for AD. Statistical analyses were performed for the whole samp…

Malemedicine.medical_specialtyPathologyAmyloid betaApolipoprotein E4tau ProteinsNeuropsychological TestsGastroenterologySensitivity and SpecificityCerebrospinal fluidAlzheimer DiseaseFluorodeoxyglucose F18Internal medicinemental disordersmedicineDementiaHumansAgedRetrospective StudiesPsychiatric Status Rating ScalesAmyloid beta-Peptidesmedicine.diagnostic_testbiologyLumbar punctureNeurodegenerationCerebrospinal Fluid ProteinsMiddle Agedmedicine.diseasePeptide FragmentsNeurologyPositron emission tomographyArea Under CurvePositron-Emission Tomographybiology.proteinFemaleNeurology (clinical)Alzheimer's diseasePsychologyCognition DisordersKappaBiomarkersFollow-Up StudiesCurrent Alzheimer research
researchProduct

Physical activity as a preventive measure for coronary heart disease risk factors in early childhood.

2004

Physical activity causes acute physiological and long-term adaptive responses in the body. It is a protective factor for coronary heart disease (CHD) in adults. It has been assumed that children younger than 8 years of age may be in general active enough and there would be hardly any relationships between physical activity and CHD risk factors in early childhood. One hundred and fifty-five children (age 4-7 years) participated in this physical activity study during three consecutive years. Physical activity was examined twice a year with a special-purpose physical activity diary. CHD risk factors were measured during annual health care visits in the Specific Turku Coronary Risk-Factor Inter…

Malemedicine.medical_specialtyPediatricsProtective factorPhysical activityPhysical Therapy Sports Therapy and RehabilitationBlood PressureCoronary DiseaseGrowthRisk FactorsInternal medicinemedicineHumansOrthopedics and Sports MedicineEarly childhoodChildExerciseFinlandbusiness.industrySerum HDL cholesterolLipidsCoronary heart diseaseBlood pressureChild PreschoolFemalebusinessChd riskLipoproteinScandinavian journal of medicinescience in sports
researchProduct

Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver

2008

SummaryAlcohol-induced fatty liver, a major cause of morbidity, has been attributed to enhanced hepatic lipogenesis and decreased fat clearance of unknown mechanism. Here we report that the steatosis induced in mice by a low-fat, liquid ethanol diet is attenuated by concurrent blockade of cannabinoid CB1 receptors. Global or hepatocyte-specific CB1 knockout mice are resistant to ethanol-induced steatosis and increases in lipogenic gene expression and have increased carnitine palmitoyltransferase 1 activity, which, unlike in controls, is not reduced by ethanol treatment. Ethanol feeding increases the hepatic expression of CB1 receptors and upregulates the endocannabinoid 2-arachidonoylglycer…

Malemedicine.medical_specialtyPhysiologyHUMDISEASEArachidonic AcidsGlyceridesMiceCarnitine palmitoyltransferase 1PiperidinesReceptor Cannabinoid CB1Internal medicineCannabinoid Receptor ModulatorsParacrine CommunicationmedicineAnimalsReceptorDiet Fat-RestrictedMolecular BiologyCells CulturedMice KnockoutCarnitine O-PalmitoyltransferaseEthanolChemistryLipogenesisFatty AcidsFatty liverCell Biologymedicine.diseaseEndocannabinoid systemCoculture TechniquesUp-RegulationMice Inbred C57BLDisease Models AnimalLipoprotein LipaseEndocrinologyLiverLipogenesisHepatocytesHepatic stellate cellPyrazoleslipids (amino acids peptides and proteins)Alcoholic fatty liverFatty Acid SynthasesRimonabantSteatosisSterol Regulatory Element Binding Protein 1Oxidation-ReductionEndocannabinoidsFatty Liver AlcoholicCell Metabolism
researchProduct

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

Alterations in the Hippocampal Endocannabinoid System in Diet-Induced Obese Mice

2010

The endocannabinoid (eCB) system plays central roles in the regulation of food intake and energy expenditure. Its alteration in activity contributes to the development and maintenance of obesity. Stimulation of the cannabinoid receptor type 1 (CB1receptor) increases feeding, enhances reward aspects of eating, and promotes lipogenesis, whereas its blockade decreases appetite, sustains weight loss, increases insulin sensitivity, and alleviates dysregulation of lipid metabolism. The hypothesis has been put forward that the eCB system is overactive in obesity. Hippocampal circuits are not directly involved in the neuronal control of food intake and appetite, but they play important roles in hed…

Malemedicine.medical_specialtyPolyunsaturated Alkamidesmedicine.medical_treatmentmedia_common.quotation_subjectArachidonic AcidsBiologyHippocampusArticlegamma-Aminobutyric acidGlyceridesMice03 medical and health sciences0302 clinical medicineReceptor Cannabinoid CB1Internal medicineCannabinoid Receptor ModulatorsCannabinoid receptor type 1medicineAnimalsObesityReceptorgamma-Aminobutyric Acid030304 developmental biologymedia_commonMice KnockoutNeurons0303 health sciencesLong-Term Synaptic DepressionGeneral NeuroscienceAppetiteDietary FatsEndocannabinoid systemMice Inbred C57BLDisease Models AnimalLipoprotein LipaseEndocrinologynervous systemSynapsesSynaptic plasticitylipids (amino acids peptides and proteins)CannabinoidDiet-induced obese030217 neurology & neurosurgeryEndocannabinoidsmedicine.drugThe Journal of Neuroscience
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct